Hantavirus vaccine development accelerates to Phase 3 trials by 2027

A leading pharmaceutical company will advance its hantavirus vaccine candidate to Phase 3 clinical trials by Q1 2027, driven by increased funding and research urgency following the outbreak. Regulatory approval timelines will tighten as global health bodies prioritize vaccine development.

Implied probability (Yes)

55%